CQDM may call on a number of national and international partner organizations potentially interested in co-financing certain projects.When possible, CQDM may offer support to applicants. Applicants are responsible for raising matched funding for the project.
CQDM pharmaceutical members must have pledged at least one third (1/3) of the funds required to support the project.Exceptionally, CQDM may consider applications exceeding the maximum, if appropriate. For scientists, the funded research opens new collaboration opportunities with world-class stakeholders in the industry.įunding of the pharma-led funding program for drug discovery researchĬQDM will review applications for its pharma-led funding program for drug discovery research subject to the following: Projects are associated with specific deliverables and must be ready for use by CQDM pharmaceutical members upon completion. The technologies of interest can be at any stage of the drug development process and involve a wide range of therapeutic indications. The enabling technologies, innovative platforms and/or innovative therapies derived from the Quantum Leap pharma-led funding program for drug discovery research are selected for their potential to significantly improve, facilitate and/or accelerate the drug discovery process and the development of safer and more effective drugs. Quantum Leap projects are executed in close collaboration and with the expert support and funds of pharmaceutical members. Projects selected as part of the Quantum Leap program focus on developing cutting-edge technologies with the potential to significantly advance the R&D activities of CQDM’s pharmaceutical members. Summary of the pharma-led funding program for drug discovery researchĬQDM’s Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects.
0 kommentar(er)
